Quantcast
Last updated on April 18, 2014 at 17:08 EDT

Latest Panitumumab Stories

2014-04-03 12:30:35

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth Monoclonal Antibodies Market in Colorectal Cancer to 2019 - Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth SummaryGBI Research, has released the pharma report "Monoclonal...

2014-01-29 23:32:09

Introducing CE-IVD marked kits with expanded mutation coverage in colorectal cancer for Kras, Nras, and Braf genes. Tarzana, Calif (PRWEB) January 29, 2014 Today EntroGen (http://www.entrogen.com) announced immediate availability of its expanded colorectal cancer screening products. EntroGen K-Ras and N-Ras Mutation Analysis kits have been updated to include coverage for exon 2, 3 and 4 mutations in both genes. The Company has obtained a CE-IVD mark for these products. The importance of...

2014-01-28 12:29:12

Science philanthropist, Jeffrey Epstein and the founder of the Program for Evolutionary Dynamics at Harvard University has helped fund pivotal research in how to combat colon cancer and specifically cancer resistance to inhibitor drugs NEW YORK, Jan. 28, 2014 /PRNewswire/ -- Science philanthropist, Jeffrey Epstein and the founder of the Program for Evolutionary Dynamics at Harvard University has helped fund pivotal research in how to combat colon cancer and specifically cancer...

2014-01-18 08:20:15

Research findings enable disease molecular sub-typing to lead to more informed clinical decision-making IRVING, Texas, Jan. 18, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, will present a large international tumor profiling study of colorectal cancer (CRC) at the 2014 Gastrointestinal Cancers Symposium this week in San Francisco, Calif. With more than 7,000 patients comprehensively profiled by...

2013-12-18 23:24:54

RnRMarketResearch.com adds “Monoclonal Antibodies Market in Colorectal Cancer to 2019 – Favorable Pricing Policy in the US and Rising Prevalence in Europe and Japan Ensures Market Growth” latest report to its store. Dallas, TX (PRWEB) December 18, 2013 There are currently three monoclonal Antibody (mAb) treatments approved for metastatic colorectal cancer with the purpose of extending the patient’s lifespan; Avastin, Erbitux and Vectibix. The current market leader is Avastin,...

2013-12-18 09:46:31

The epidermal growth factor receptor (EGFR) is expressed in normal colonic cells and is activated by specific peptide growth factors that regulate cell proliferation, survival and differentiation. Increased expression and activation of the EGFR has been observed in the majority of colorectal carcinoma (CRC), suggesting that the EGFR pathway plays an important role in colon carcinogenesis. The monoclonal antibodies cetuximab and panitumumab are capable of blocking EGFR activity and have...

2013-12-12 23:00:14

ResearchMoz.us include new market research report "Monoclonal Antibodies Market in Colorectal Cancer to 2019" to its huge collection of research reports. Click here to download detail report at http://www.researchmoz.us/monoclonal-antibodies-market-in-colorectal-cancer-to-2019-favorable-pricing-policy-in-the-us-and-rising-prevalence-in-europe-and-japan-ensures-market-growth-report.html. Albany, New York (PRWEB) December 13, 2013 GBI Research, has released the pharma report -...

2013-10-17 08:29:17

LAUSANNE, Switzerland, MECHELEN, Belgium and BARCELONA, Spain, October 17, 2013 /PRNewswire/ -- Today Biocartis and Hospital del Mar announced their licence agreement on the EGFR biomarker for colon cancer. This agreement enables Biocartis to develop a new colon cancer test, whereby a specific EGFR mutation can be rapidly and accurately detected in patients, which will enable doctors to recommend personalised therapy. Innovative platforms and tests for cancer diagnosis...

2013-10-02 08:29:47

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, October 2, 2013 /PRNewswire/ -- Today, Investors' Reports announced new research reports highlighting Celgene Corporation (NASDAQ: CELG), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Nektar Therapeutics (NASDAQ: NKTR), and Zalicus Inc. (NASDAQ: ZLCS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings...

2013-09-28 04:20:17

Trial Evaluated Nearly 1,000 Patients With Metastatic Colorectal Cancer THOUSAND OAKS, Calif., Sept. 28, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 ASPECCT ('763) trial comparing Vectibix(®) (panitumumab) to Erbitux(®) (cetuximab) for the treatment of wild-type KRAS metastatic colorectal cancer in patients who have not responded to chemotherapy. The study met its primary endpoint, demonstrating that panitumumab was non-inferior to cetuximab...